Inclusion Criteria:

          -  Histological or cytological proof of metastatic NSCLC; for PART B: treated with first
             line therapy for metastatic disease only.

          -  Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA
             wild-type (exon 9 and 20)

          -  Age ≥ 18 years

          -  Able and willing to give written informed consent

          -  WHO performance status of 0 or 1 (part A and B)

        Exclusion Criteria:

          -  Any treatment with investigational drugs within 30 days prior to receiving the first
             dose of investigational treatment.

          -  History of another primary malignancy

          -  Symptomatic or untreated leptomeningeal disease

          -  Symptomatic brain metastasis

          -  History of interstitial lung disease or pneumonitis

          -  Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2
             type patients

          -  Retinal degenerative disease (hereditary retinal degeneration or age-related macular
             degeneration), or a history of uveitis, retinal vein occlusion, central serous
             retinopathy, or retinal detachment

          -  Patients with left ventricular ejection fraction (LVEF) < 50%